HC Wainwright reiterated their buy rating on shares of Presbia (NASDAQ:LENS) in a research note released on Wednesday, December 20th, MarketBeat reports. The firm currently has a $7.00 price objective on the medical instruments supplier’s stock.
Other equities analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Presbia from a sell rating to a hold rating in a research note on Tuesday, December 5th. Jefferies Group reissued a buy rating and issued a $10.00 price target (down from $11.00) on shares of Presbia in a research note on Friday, October 6th. Finally, ValuEngine raised shares of Presbia from a strong sell rating to a sell rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $9.67.
Shares of Presbia (NASDAQ LENS) traded down $0.10 during trading hours on Wednesday, hitting $3.42. 10,355 shares of the stock traded hands, compared to its average volume of 230,406. The company has a market capitalization of $60.27, a P/E ratio of -2.85 and a beta of 0.03. The company has a current ratio of 3.02, a quick ratio of 2.94 and a debt-to-equity ratio of 0.07. Presbia has a 52-week low of $1.86 and a 52-week high of $7.14.
An institutional investor recently raised its position in Presbia stock. FMR LLC raised its holdings in shares of Presbia PLC (NASDAQ:LENS) by 0.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,568,278 shares of the medical instruments supplier’s stock after purchasing an additional 13,375 shares during the period. FMR LLC owned 15.15% of Presbia worth $5,856,000 as of its most recent SEC filing. 16.05% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Presbia’s (LENS) “Buy” Rating Reaffirmed at HC Wainwright” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/14/presbia-lens-stock-rating-reaffirmed-by-hc-wainwright.html.
Presbia Company Profile
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.